Korea/Asia, Events, IPOs, Douglas Research Advisory

Douglas Kim

Korea/Asia, Events, IPOs

Thematic (Sector/Industry)

<p>This year appears to be an exciting year for IPOs in Korea, barring a dramatic downturn in global equities markets like the one we experienced in 2008. In this report, we highlight some of the major IPOs that are in the pipeline for 2016. Recapping 2015, there were 128 companies in Korea that completed IPOs (including 19 new listings in KOSPI and 109 new listings in KOSDAQ markets). </p><p>The IPO market in Korea is off to a solid start. JS Corporation (194370KS), a leading ODM (original design…</p>

This year appears to be an exciting year for IPOs in Korea, barring a dramatic downturn in global equities markets like the one we experienced in 2008. In this report, we highlight some of the major IPOs that are in the pipeline for 2016. Recapping 2015, there were 128 companies in Korea that completed IPOs (including 19 new listings in KOSPI and 109 new listings in KOSDAQ markets). The IPO market in Korea is off to a solid start. JS Corporation (194370KS), a leading ODM (original design…

Global Healthcare Analyst

Tina Banerjee

Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/hugel-inc" target="_blank" data-smartkarma-citation="entities:22860:1" rel="noopener">Hugel Inc (145020 KS)</a> reported 2025 results with revenue of KRW425B, operating profit of KRW202B, and net profit of KRW144B. The results represent the highest in the company’s history.</li>
<li>This year, Hugel will pursue "hybrid sales" strategy, combining distribution through existing partners with direct sales in the U.S., which should improve profitability, driving stable sales, and market share expansion.</li>
<li>Hugel has set a target of KRW900B revenue by 2028 (2025–2028 CAGR: 28%), with US sales accounting for 30% of total sales and maintaining industry leading operating profit margin.</li>
</ul>



Hugel Inc (145020 KS) reported 2025 results with revenue of KRW425B, operating profit of KRW202B, and net profit of KRW144B. The results represent the highest in the company’s history.
This year, Hugel will pursue "hybrid sales" strategy, combining distribution through existing partners with direct sales in the U.S., which should improve profitability, driving stable sales, and market share expansion.
Hugel has set a target of KRW900B revenue by 2028 (2025–2028 CAGR: 28%), with US sales accounting for 30% of total sales and maintaining industry leading operating profit margin.


Hugel Inc (145020 KS): Record High Result for 2025; Eyes U.S.-Led Growth Strategy Ahead

<ul>
<li>
<a href="https://www.smartkarma.com/entities/hugel-inc" target="_blank" data-smartkarma-citation="entities:22860:1" rel="noopener">Hugel Inc (145020 KS)</a> has reported strong 2Q25 result, with all key parameters marking the highest quarterly figures in the company's history and contributed to a record first-half performance.</li>
<li>Overseas revenue of toxin and derma fillers rose 21% YoY to KRW70B, accounting for 63% of the company's total sales, boosted by robust growth in the U.S., China, and Europe.</li>
<li>Hugel is well-positioned to report ~20% annual revenue growth through 2027 through global expansion amid favorable industry backdrop.</li>
</ul>



Hugel Inc (145020 KS) has reported strong 2Q25 result, with all key parameters marking the highest quarterly figures in the company's history and contributed to a record first-half performance.
Overseas revenue of toxin and derma fillers rose 21% YoY to KRW70B, accounting for 63% of the company's total sales, boosted by robust growth in the U.S., China, and Europe.
Hugel is well-positioned to report ~20% annual revenue growth through 2027 through global expansion amid favorable industry backdrop.


Hugel Inc (145020 KS): Strong Overseas Sales Drive 2Q Performance; Positive Outlook

<ul>
<li>
<a href="https://www.smartkarma.com/entities/hugel-inc" target="_blank" data-smartkarma-citation="entities:22860:1" rel="noopener">Hugel Inc (145020 KS)</a> reported strong 1Q25 result, with all key parameters recording double-digit growth. The robust growth was driven by balanced gains across all product portfolios.</li>
<li>In March, Hugel has fully commercialized Letybo in the U.S. through the partnership with Benev. The company aims to capture 10% market share in the U.S. within three years.</li>
<li>Earlier this month, Hugel has officially launched Botulax in UAE. This marked the second official launch in the Middle East, following the product’s debut in Kuwait.</li>
</ul>



Hugel Inc (145020 KS) reported strong 1Q25 result, with all key parameters recording double-digit growth. The robust growth was driven by balanced gains across all product portfolios.
In March, Hugel has fully commercialized Letybo in the U.S. through the partnership with Benev. The company aims to capture 10% market share in the U.S. within three years.
Earlier this month, Hugel has officially launched Botulax in UAE. This marked the second official launch in the Middle East, following the product’s debut in Kuwait.


Hugel Inc (145020 KS): Record High 1Q Earnings; US Commercialization and UAE Debut to Trigger Growth

<ul>
<li>
<a href="https://www.smartkarma.com/entities/hugel-inc" target="_blank" data-smartkarma-citation="entities:22860:1" rel="noopener">Hugel Inc (145020 KS)</a> reported record high sales, operating profit, and net profit in 2024, with the strong performance of botulinum toxin and fillers backed by the company’s global expansion.</li>
<li>Hugel aims to launch botulinum toxin in the U.S. within 1H25. The company aims for a 10% U.S. market share for aesthetic purposes within three years from the product release.</li>
<li>Hugel aims to expand its presence in more than 80 toxin markets (from 67 now), 70 dermal filler markets (current 52), and more than 10 cosmetics markets by 2028.</li>
</ul>



Hugel Inc (145020 KS) reported record high sales, operating profit, and net profit in 2024, with the strong performance of botulinum toxin and fillers backed by the company’s global expansion.
Hugel aims to launch botulinum toxin in the U.S. within 1H25. The company aims for a 10% U.S. market share for aesthetic purposes within three years from the product release.
Hugel aims to expand its presence in more than 80 toxin markets (from 67 now), 70 dermal filler markets (current 52), and more than 10 cosmetics markets by 2028.


Hugel Inc (145020 KS): Record High Performance in 2024; Continued Global Expansion to Drive Growth

South Korea

Medy-Tox Inc. is a biopharmaceutical company.  The Company researches, develops and manufactures biopharmaceutical products using clostridium botulinum which is a microorganism toxin.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Medy Tox Inc (086900 KS)

2016 Major IPOs Pipeline in Korea

This year appears to be an exciting year for IPOs in Korea, barring a dramatic downturn in global equities markets like the one we experienced in...

Douglas Kim

Hugel Inc (145020 KS): Record High Result for 2025; Eyes U.S.-Led Growth Strategy Ahead

Hugel reports double-digit revenue and operating profit growth in 2025. The company plans to pursue hybrid sales strategy in the US to drive...

Tina Banerjee

Hugel Inc (145020 KS): Strong Overseas Sales Drive 2Q Performance; Positive Outlook

Hugel reports record-breaking 2Q25 results with overseas revenue driving strong growth. Overseas revenue rose 21% YoY to KRW70B, accounting for...

Tina Banerjee

Hugel Inc (145020 KS): Record High 1Q Earnings; US Commercialization and UAE Debut to Trigger Growth

Hugel reports double-digit growth across all key parameters in 1Q25, driven by balanced gains in all product portfolios. The company aims to...

Tina Banerjee

Hugel Inc (145020 KS): Record High Performance in 2024; Continued Global Expansion to Drive Growth

Hugel achieves record sales and profits in 2024, driven by strong performance across all segments. US launch of toxin is expected in 1H25. Hugel...

Tina Banerjee

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

2016 Major IPOs Pipeline in Korea

This year appears to be an exciting year for IPOs in Korea, barring a dramatic downturn in global equities markets like the one we experienced in...

Douglas Kim

Hugel Inc (145020 KS): Record High Result for 2025; Eyes U.S.-Led Growth Strategy Ahead

​Hugel reports double-digit revenue and operating profit growth in 2025. The company plans to pursue hybrid sales strategy in the US to drive...

Tina Banerjee

Hugel Inc (145020 KS): Strong Overseas Sales Drive 2Q Performance; Positive Outlook

​Hugel reports record-breaking 2Q25 results with overseas revenue driving strong growth. Overseas revenue rose 21% YoY to KRW70B, accounting for...

Tina Banerjee

Hugel Inc (145020 KS): Record High 1Q Earnings; US Commercialization and UAE Debut to Trigger Growth

​Hugel reports double-digit growth across all key parameters in 1Q25, driven by balanced gains in all product portfolios. The company aims to...

Tina Banerjee

Hugel Inc (145020 KS): Record High Performance in 2024; Continued Global Expansion to Drive Growth

​Hugel achieves record sales and profits in 2024, driven by strong performance across all segments. US launch of toxin is expected in 1H25. Hugel...

Tina Banerjee

Hugel reports double-digit revenue and operating profit growth in 2025. The company plans to pursue hybrid sales strategy in the US to drive...

Hugel reports record-breaking 2Q25 results with overseas revenue driving strong growth. Overseas revenue rose 21% YoY to KRW70B, accounting for...

Hugel reports double-digit growth across all key parameters in 1Q25, driven by balanced gains in all product portfolios. The company aims to...

Hugel achieves record sales and profits in 2024, driven by strong performance across all segments. US launch of toxin is expected in 1H25. Hugel...